S6K1 Alternative Splicing Modulates Its Oncogenic Activity and Regulates mTORC1
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Ribosomal S6 kinase 1 (S6K1) is a major mTOR downstream signaling molecule that regulates cell size and translation efficiency. Here, we report that short isoforms of S6K1 are overproduced in breast cancer cell lines and tumors. Overexpression of S6K1 short isoforms induces transformation of human breast epithelial cells. The long S6K1 variant (Iso-1) induced opposite effects. It inhibits Ras-induced transformation and tumor formation, while its knockdown or knockout induces transformation, suggesting that Iso-1 has a tumor-suppressor activity. Furthermore, we found that S6K1 short isoforms bind and activate mTORC1, elevating 4E-BP1 phosphorylation, cap-dependent translation, and Mcl-1 protein levels. Both a phosphorylation-defective 4E-BP1 mutant and the mTORC1 inhibitor rapamycin partially blocked the oncogenic effects of S6K1 short isoforms, suggesting that these are mediated by mTORC1 and 4E-BP1. Thus, alternative splicing of S6K1 acts as a molecular switch in breast cancer cells, elevating oncogenic isoforms that activate mTORC1.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
AKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro
Liang, C.-C., Park, A. Y., & Guan, J.-L. (2007) · Nature Protocols · doi:10.1038/nprot.2007.30 · Cited by 4,696 · cited 2×
“MCF-10A cells were seeded in a 6 well plate until formation of a confluent monolayer, and a “wound” was created by scratching the monolayer with a p200 pipette tip as described in (Liang et al., 2007).”
MethodmTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941 · cited 3×
“Several components of the mTOR signaling cascade have been identified as oncogenes or tumor suppressors that activate or repress this pathway respectively (Zoncu et al., 2011) (Shaw and Cantley, 2006).”
BackgroundSarbassov, D. D., Ali, S. M., Kim, D.-H., Guertin, D. A., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2004) · Current Biology · doi:10.1016/j.cub.2004.06.054 · Cited by 2,665
Ras, PI(3)K and mTOR signalling controls tumour cell growth
Shaw, R. J., & Cantley, L. C. (2006) · Nature · doi:10.1038/nature04869 · Cited by 2,019 · cited 3×
“Insulin/IGF-1 and EGF activate their corresponding receptors leading to activation of several mitogenic signaling cascades, among them the Ras-Raf-MAPK-ERK and the PI3K-AktmTOR pathways (Shaw and Cantley, 2006) (Yuan and Cantley, 2008) (Mendoza et al., 2011).”
BackgroundMethodPI3K pathway alterations in cancer: variations on a theme
Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845
The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation
Mendoza, M. C., Er, E. E., & Blenis, J. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2011.03.006 · Cited by 1,817
Holz, M. K., Ballif, B. A., Gygi, S. P., & Blenis, J. (2005) · Cell · doi:10.1016/j.cell.2005.10.024 · Cited by 1,262
Regulation of cytoplasmic mRNA decay
Schoenberg, D. R., & Maquat, L. E. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3160 · Cited by 656 · cited 1×
“…of a poly adenylation sequence, and in the case of h6A also a premature stop codon (PTC) located less then 55bp from the next exon junction complex, prevents degradation of the generated transcripts by the Nonsence Mediated Decay (NMD) mechanism (Figs 1A. S1E) (Schoenberg and Maquat, 2012).”
BackgroundmTOR, translation initiation and cancer
Mamane, Y., Petroulakis, E., LeBacquer, O., & Sonenberg, N. (2006) · Oncogene · doi:10.1038/sj.onc.1209888 · Cited by 607 · cited 2×
“…one of the major signaling pathways hyper activated in many cancers, and leads to uncontrolled proliferation, increased survival, motility and invasiveness of cancer cells (Mamane et al., 2006; Manning and Cantley, 2007; Yuan and Correspondence should be addressed to R.K. (rotemka@ekmd.huji.ac.il).”
BackgroundZhan, L., Rosenberg, A., Bergami, K. C., Yu, M., Xuan, Z., Jaffe, A. B., Allred, C., & Muthuswamy, S. K. (2008) · Cell · doi:10.1016/j.cell.2008.09.045 · Cited by 436 · cited 1×
“Following selection, 1500 cells per well were seeded in 96-well in Growth factor- reduced Matrigel (BD Bioscience, Cat# 25300), as described in (Zhan et al., 2008).”
MethodShe, Q.-B., Halilovic, E., Ye, Q., Zhen, W., Shirasawa, S., Sasazuki, T., Solit, D. B., & Rosen, N. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.023 · Cited by 400 · cited 4×
“We next examined, using two complementary strategies, if this activation is required for their oncogenic activities: 1) Inhibition of mTORC1 by the pharmacological inhibitor rapamycin and 2) expression of a phosphorylation-defective 4E-BP1 which is mutated in its phosphorylation sites and cannot dissociate from eIF4E…”
BackgroundMethodInfluentialOhanna, M., Sobering, A. K., Lapointe, T., Lorenzo, L., Praud, C., Petroulakis, E., Sonenberg, N., Kelly, P. A., Sotiropoulos, A., & Pende, M. (2005) · Nature Cell Biology · doi:10.1038/ncb1231 · Cited by 392 · cited 3×
“S6K1 has been implicated in the regulation of cell size (Ohanna et al., 2005) and its role in transformation is controversial; in some reports it seems dispensable for transformation (Hsieh et al.”
BackgroundmTORC1 promotes survival through translational control of Mcl-1
Mills, J. R., Hippo, Y., Robert, F., Chen, S. M. H., Malina, A., Lin, C.-J., Trojahn, U., Wendel, H.-G., Charest, A., Bronson, R. T., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804821105 · Cited by 285 · cited 2×
“One such protein is Mcl-1 (Hsieh et al., 2010), a key antiapoptotic protein that was shown to be translationaly controlled by mTORC1 (Mills et al., 2008).”
BackgroundActivated pp60c-Src Leads to Elevated Hypoxia-inducible Factor (HIF)-1α Expression under Normoxia
Karni, R., Dor, Y., Keshet, E., Meyuhas, O., & Levitzki, A. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m206141200 · Cited by 116
Self-citation
Cited by
RNA splicing dysregulation and the hallmarks of cancer
Bradley, R. K., & Anczuków, O. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-022-00541-7 · Cited by 579
Regulation of splicing by SR proteins and SR protein-specific kinases
Zhou, Z., & Fu, X.-D. (2013) · Chromosoma · doi:10.1007/s00412-013-0407-z · Cited by 478
Urbanski, L. M., Leclair, N., & Anczuków, O. (2018) · WIREs RNA · doi:10.1002/wrna.1476 · Cited by 389
Signaling Pathways Involved in the Regulation of mRNA Translation
Roux, P. P., & Topisirovic, I. (2018) · Molecular and Cellular Biology · doi:10.1128/mcb.00070-18 · Cited by 324
Malakar, P., Shilo, A., Mogilevsky, A., Stein, I., Pikarsky, E., Nevo, Y., Benyamini, H., Elgavish, S., Zong, X., Prasanth, K. V., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-1508 · Cited by 317
Self-citation
Metadata
- Authors
- Ben-Hur, V., Denichenko, P., Siegfried, Z., Maimon, A., Krainer, A., Davidson, B., & Karni, R.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2013-01
- Volume
- 3
- Issue
- 1
- Pages
- 103-115
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W2168379252
- Cited by
- 129
- References
- 15
- FWCI
- 2.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.